The Resurgence of Antibody Drug Conjugates: How ADCs are taking over oncology (again) and what we’ve learned about creating bioanalytical methods to support preclinical and clinical success.

Michelle Miller, PhD, Global Senior Scientific Director, Bioanalytical Services What is an ADC? Antibody Drug Conjugates (ADCs) consist of a monoclonal antibody linked to a cytotoxic payload. The antibody binds to a cancer antigen, resulting in the targeted delivery of the payload to the tumor site.